Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Flaherty

Showing results (351-360 of 580) with videos related to

Pageof 58
Sort By:
Child and Adolescent Psychiatry and Mental Health|April 23, 2019
Shaping the future of child and adolescent psychiatryNorbert Skokauskas, Daniel Fung, Lois T Flaherty, et al.
Molecular Cancer Therapeutics|September 16, 2008
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomasKeiran S M Smalley, Mercedes Lioni, Maurizia Dalla Palma, et al.
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
Cancer Cell|July 7, 2007
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced deathM Stacey Ricci, Seok-Hyun Kim, Kazuhiro Ogi, et al.
Journal for Immunotherapy of Cancer|June 21, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)Hussein A Tawbi, Caroline Robert, Jan C Brase, et al.
Melanoma Research|September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanomaShalin Shah, Jason J Luke, Heather A Jacene, et al.
Nature Medicine|August 9, 2016
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanomaChe-Hung Shen, Sun Hye Kim, Sebastian Trousil, et al.
Journal of Translational Medicine|September 30, 2024
Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastomaHao Duan, Yuan Xie, Suwen Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2015
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in MelanomaMelissa A Wilson, Fengmin Zhao, Sanika Khare, et al.
BJU International|September 4, 2021
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805Jose A Karam, Maneka Puligandla, Keith T Flaherty, et al.
Pageof 58

Showing results (351-360 of 580) with videos related to

Sort By:
Pageof 58
Child and Adolescent Psychiatry and Mental Health|April 23, 2019
Shaping the future of child and adolescent psychiatryNorbert Skokauskas, Daniel Fung, Lois T Flaherty, et al.
Molecular Cancer Therapeutics|September 16, 2008
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomasKeiran S M Smalley, Mercedes Lioni, Maurizia Dalla Palma, et al.
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
Cancer Cell|July 7, 2007
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced deathM Stacey Ricci, Seok-Hyun Kim, Kazuhiro Ogi, et al.
Journal for Immunotherapy of Cancer|June 21, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)Hussein A Tawbi, Caroline Robert, Jan C Brase, et al.
Melanoma Research|September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanomaShalin Shah, Jason J Luke, Heather A Jacene, et al.
Nature Medicine|August 9, 2016
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanomaChe-Hung Shen, Sun Hye Kim, Sebastian Trousil, et al.
Journal of Translational Medicine|September 30, 2024
Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastomaHao Duan, Yuan Xie, Suwen Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2015
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in MelanomaMelissa A Wilson, Fengmin Zhao, Sanika Khare, et al.
BJU International|September 4, 2021
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805Jose A Karam, Maneka Puligandla, Keith T Flaherty, et al.
Pageof 58